Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0767 Added to Insulin in Type 2 Diabetes
NCT00543816Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2003
- Primary completion
- Nov 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK0767 + Insulin with Placebo + Insulin (2 arms). Primary endpoint: Hemoglobin A1c at 12 weeks. Started Aug 2003; status: terminated.
02
Drugs
MK-767
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00543816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543816.